TITLE

Diabetes clinical studies

PUB. DATE
May 2012
SOURCE
Nephrology Dialysis Transplantation;May2012 Supplement 2, Vol. 27 Issue suppl_2, pii55
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
76281160

 

Related Articles

  • Update in Nephrology: Evidence Published in 2013. Roumelioti, Maria-Eleni; Unruh, Mark // Annals of Internal Medicine;7/1/2014, Vol. 161 Issue 1, p54 

    The reviews studies in nephrology, transplantation, and hypertension that are relevant to primary care as of 2014. The topics discussed include a clinical trial in dual renin–angiotensin–aldosterone system (RAAS) blockade for treatment of Diabetic nephropathies, and epidemiological...

  • Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Kato, Sawako; Maruyama, Shoichi; Makino, Hirofumi; Wada, Jun; Ogawa, Daisuke; Uzu, Takashi; Araki, Hisazumi; Koya, Daisuke; Kanasaki, Keizo; Oiso, Yutaka; Goto, Motomitsu; Nishiyama, Akira; Kobori, Hiroyuki; Imai, Enyu; Ando, Masahiko; Matsuo, Seiichi // Clinical & Experimental Nephrology;Dec2015, Vol. 19 Issue 6, p1098 

    Background: Several studies have demonstrated that spironolactone has an anti-albuminuric property in diabetic nephropathy. As an adverse event, spironolactone often induces the elevation of creatinine levels with hypotension and hyperkalemia. Therefore, we aimed to evaluate the efficacy and...

  • The angiotensin receptor blocker and PPAR-γ agonist, telmisartan, delays inactivation of voltage-gated sodium channel in rat heart: novel mechanism of drug action. Kim, Hyoung; Youm, Jae; Lee, Sung; Lim, Se; Lee, Sun-Young; Ko, Tae; Long, Le; Nilius, Bernd; Won, Du; Noh, Jung-Hyun; Ko, Kyung; Rhee, Byoung; Kim, Nari; Han, Jin // Pflugers Archiv European Journal of Physiology;Dec2012, Vol. 464 Issue 6, p631 

    Telmisartan is an angiotensin II receptor blocker and partial peroxisome proliferator-activated receptor gamma agonist that modulates the renin-angiotensin-aldosterone system. It is used primarily to manage hypertension, diabetic nephropathy, and congestive heart failure. Recent studies have...

  • Podocyte ACE2 protects against diabetic nephropathy. Harris, Raymond C // Kidney International;Aug2012, Vol. 82 Issue 3, p255 

    As new components of the renin-angiotensin system (RAS) are elucidated, our understanding of the complexities of their interactions also advances. Previous studies have determined that podocytes possess a local RAS that can generate angiotensin II. Podocytes have also been shown to express...

  • Complete Blockade of the Renin-Angiotensin System in Patients With Advanced Diabetic Nephropathy. Deira, Javier; Diaz, Hugo; Grande, Jesús // Diabetes Care;May2003, Vol. 26 Issue 5, p1635 

    Comments on an article by K. Rossing and colleagues on the complete blockade of the renin-angiotensin system in patients with advanced diabetic nephropathy. Study of patients on prior treatment with ACE inhibitors; Calculation of glomerular filtration rate; Decrease in proteinuria and in total...

  • Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Jacobsen, Peter; Andersen, Steen; Rossing, Kasper; Jensen, Berit R.; Parving, Hans-Henrik // Kidney International;May2003, Vol. 63 Issue 5, p1874 

    Background: Albuminuria and hypertension are predictors of poor renal and cardiovascular outcome in diabetic patients. We tested whether dual blockade of the renin-angiotensin system (RAS) with both an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor...

  • Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy. Shinji Kume; Daisuke Koya // Diabetes & Metabolism Journal;Dec2015, Vol. 39 Issue 6, p451 

    Diabetic nephropathy is a leading cause of end stage renal disease and its occurance is increasing worldwide. The most effective treatment strategy for the condition is intensive treatment to strictly control glycemia and blood pressure using renin-angiotensin system inhibitors. However, a...

  • Angiotensin II receptor antagonists in hypertension. Burnier, Michel; Brunner, Hans R. // Kidney International;Dec1998 Supplement 68, Vol. 54, pS107 

    Angiotensin II receptor antagonists in hypertension. Blockade of the renin-angiotensin system is now recognized as an effective approach to the treatment of hypertension and congestive heart failure. Today, it is possible to antagonize the effects of angiotensin II more specifically by blocking...

  • Present and Future in the Treatment of Diabetic Kidney Disease. Quiroga, Borja; Arroyo, David; de Arriba, Gabriel // Journal of Diabetes Research;4/7/2015, Vol. 2015, p1 

    Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression. For this reason, blockade of renin-angiotensin system remains the main recommended strategy, with either angiotensin...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics